Thiago P. Muniz

Happy to do teaching for a living.

#MedicalOncology #MedicalEducation

Today is Medical Oncologist’s Day in Brazil. Congrats to all my Med Onc Colleagues! May we continue to treat patients carefully and based on science! 🔪🦀

PMH at #ASCO25 #NeuroOncology

My takeaways from CNS abstract session at #ASCO25
- No need of concurrent TMZ in grade 3 IDHm gliomas, non-1p/19q co-deleted. 12 cycles of adjuvant post-rads remains SOC.
- Exciting emerging therapies for LMD (HER3-Dxd)
- Potential for cell therapies in GBM. Larger trials are needed.

Great educational session at #ASCO25 discussing targeted therapies in neuro-oncology. We do need to understand molecular subgroups, which drugs are actually effective in CNS, and finally, who does actually benefit from IDHi?

Excited to be attending #ASCO25. Starting off by watching an educational session on targeted therapy in neuro-oncology. The afternoon will continue with Neuro-Oncology Oral Abstract Sessions.

So, I’ve just heard that US and Canada will become one big country called Panem and we will be wishing that our tributes win the Hunger Games.

Merry Christmas and Happy Holiday to everyone here on BlueSky. May everyone spend this day with their loved ones.

I was in São Paulo on November 29 discussing the practical management of tebentafusp in metastatic #uvealmelanoma. Glad to have Dr. Mirela Nardo and Dr. Rodrigo Munhoz joining the discussion. Hopefully, the drug will be soon approved in Brazil.

I was at AC Camargo Cancer Center, Brazil today to share experience on the management of patients with #uvealmelanoma. It is gratifying to be back to my teaching hospital and share the knowledge with future Brazilian Medical Oncologists! I hope to be back in other opportunities. #MedicalEducation

Hi all, I’ve been trying to access the LUMPO3 for the past few days and I’ve been getting an error message. Is this just me or is it happening to anyone else?
#uvealmelanoma #melanoma

Feel free to add me :)

Bespoke ctDNA for longitudinal detection of molecular residual disease in high-risk melanoma patients Locally advanced melanoma has a variable prognosis. Currently, there are no reliable criteria to stratify the risk of disease relapse and identify tho…

Sharing our publication on the role of ctDNA in high risk melanoma patients, led by Dr. Sofia Genta. Glad to be part of the melanoma team at Princess Margaret.

www.sciencedirect.com/science/arti...

Hi there! Oncologist practicing in Canada here! :)

It seems that there was a migration to BlueSky.
So, let me introduce myself: My name is Thiago Muniz. I’m from Brazil and I’m a Medical Oncologist at Princess Margaret in Toronto. My focus is skin cancers, brain tumors, and brain mets. I’m also a clinician teacher. Let’s connect! :)

This past month, I received communications from two different students who felt I helped them achieving their goals. That is the most gratifying thing for a clinician teacher!
#MedicalEducation

Hi, everyone :)

3-4 months as a staff and already had one patient with ICI-related carditis after one dose of single agent anti-PD1. Rare, but it happens.

Ok, now I will try to migrate here definitely. Spread the word.

Higher excess mortality rates among Republican as compared to Democratic voters after full availability of COVID-19 vaccines. It makes me wonder what the results would be if a similar study was made in Brazil

https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2807617

Today we celebrate the Medical Oncologist’s Day in Brazil! Congratulations to all the colleagues practicing in this wonderful and challenging specialty!

Nice review on how to perform cranial nerves examination.

https://www.nejm.org/doi/full/10.1056/NEJMvcm2103640

I arrived in Canada 4 years ago today. Many challenges, many lessons learned, no regrets.

Glad for the opportunity of seeing and helping in the care of patients on this trial during my Fellowship in Neuro-Oncology at Princess Margaret.

Vorasidenib is well tolerated and achieved an important endpoint of delaying radiation and chemotherapy, therefore sparing patients from toxicities. One should bear in mind that these are young patients (~40yo) for whom delaying chemo/RT is particularly important.

Thrilling to be living these exciting times of practice change in low-grade IDHmut #gliomas. Results of the INDIGO trial show that vorasidenib has improved PFS and Time to Next Intervention for patients not treated with chemo or RT.

The success of targeted therapy in patients with BRAF-mutant gliomas shows that genomic-directed therapies can be beneficial for patients with primary brain tumors. It is time to advance personalized medicine for this patient population.

Resistance to targeted therapy is always a concern when treating this population. We also reviewed the data on mechanisms of resistance and what is being tested in the preclinical and clinical setting to address this important issue.

Interestingly, for low-grade gliomas, monotherapy with BRAF inhibitor may lead to extended disease control and survival, and most patients may be rescued with the addition of a MEK inhibitor on recurrence. For high-grade gliomas, combination upfront is advisable.

Targeted therapy resulted in tumor shrinkage, improved progression-free survival and overall survival in patients with different glioma subtypes. This was achieved in patients who had failed prior treatments, which makes these results even more remarkable.